In 2023, the 340B drug discount program recorded a record high of $66.3 billion in drug purchases, according to program data. This scale has prompted Senator Bill Cassidy to introduce a bill aimed at reining in its rapid growth, according to Stat News. This legislative effort signals a serious intent from a key Senate committee to address perceived issues within the rapidly expanding program.
The 340B program was designed to support safety-net providers for vulnerable patients, yet it has evolved into a massive revenue generator for some of the largest hospital systems. This divergence from its original purpose has fueled widespread debate over its current structure.
The Cassidy bill is a significant legislative effort to redefine the scope and beneficiaries of the 340B program, likely leading to a contentious battle between hospitals, drug manufacturers, and patient advocacy groups over billions in drug discounts.
- The 340B Program reached a record high of $66.3 billion in drug purchases in 2023, according to program data.
- Bon Secours Mercy Health and Cleveland Clinic generated hundreds of millions of dollars in 340B revenue, according to program data.
- Drug manufacturers report significantly increasing 340B sales to contract pharmacies compared to direct sales to hospitals and grantees, according to industry reports.
- The 340B ceiling price for a specialty drug with a WAC list price of $5,000 is approximately $1,250, reflecting a 75% discount from the WAC list price, according to Drug Channels.
- Senator Bill Cassidy released a draft discussion bill to make changes to the 340B hospital drug discount program, according to Bloomberg Government News.
- The discussion draft aims to fix the 340B drug discount program, according to Fierce Healthcare.
The 340B Program's Explosive Growth and Cassidy's Call for Reform
The 340B program's drug purchases hit $66.3 billion in 2023, according to program data. The $66.3 billion in drug purchases indicates a program operating at a massive financial scale. Large hospital systems, including Bon Secours Mercy Health and Cleveland Clinic, generated hundreds of millions of dollars in 340B revenue, according to program data.
This revenue generation for major healthcare entities, not typically seen as primary safety-net providers, highlights the program's unexpected financial beneficiaries. The record $66.3 billion in 340B drug purchases in 2023, coupled with major hospital systems like Bon Secours Mercy Health and Cleveland Clinic generating hundreds of millions in revenue, reveals a program that has morphed into a profit engine for large healthcare entities, rather than a lifeline for the truly vulnerable.
How Contract Pharmacies and Deep Discounts Shape 340B
Drug manufacturers report a significant increase in 340B sales directed to contract pharmacies, surpassing direct sales to hospitals and grantees, according to industry reports. The significant increase in 340B sales directed to contract pharmacies suggests contract pharmacies have become central to the program's financial mechanics.
Deep discounts further complicate the program's financial structure. For example, a specialty drug with a $5,000 WAC list price receives a 340B ceiling price of approximately $1,250, a 75% discount, according to Drug Channels. Senator Cassidy's proposed reforms directly challenge a lucrative financial model where drug manufacturers' discounts, intended for safety nets, are instead bolstering the bottom lines of contract pharmacies and large hospital systems, signaling a potential seismic shift in healthcare economics. If enacted, Cassidy's bill could significantly alter the program's $66.3 billion financial landscape, according to program data from 2023.
